The independent source for health policy research, polling, and news.
2,441-2,460 of 4,033 results
In this chat, KHN senior correspondent Jay Hancock discusses how drug-pricing battles could play out this year in D.C., state legislatures and beyond. What do we know about the drug industry’s agenda to quiet the drumbeat of cost control and transparency proposals? How will they officials target their efforts? Will the battles take place at the state level? Senior editor Stephanie Stapleton moderates.
The Haight Ashbury Free Clinic still serves people living on the fringes in San Francisco. This radio story recounts its 51-year history.
The Affordable Care Act mandated that hospitals exempt from taxes work to provide health benefits to the community. But a study finds that has been slow to get off the ground.
The Republican senator sent out letters to the Food and Drug Administration and HHS demanding an explanation about a rogue herpes vaccine trial.
Seven states saw a third or more of their hospitals punished under the federal heath law’s campaign against hospital-acquired conditions.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Laws in California and most other states allow pharmacists to provide naloxone to patients or their friends without a doctor’s prescription. But many don’t do so, citing lack of demand and awareness among patients, their own fears of insufficient compensation and the challenges of treating opioid users.
Dr. Rana Awdish was completing a fellowship in critical care when she became critically ill herself. Now, she helps other doctors understand the patient’s perspective.
Increasingly, owners of nursing homes outsource services to companies in which they also have financial interest or control. That allows the nursing homes to claim to be in the red while owners reap hidden profits.
Medicare is discouraging regional offices from levying fines for “one-time mistakes” or from using daily fines that seek to put pressure on nursing homes to make changes.
Premature death, a dearth of treatments, mistreatment in emergency rooms and a woeful lack of funding are just a few of the problems confronting people with sickle cell disease.
The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
Drugs that treat rheumatoid arthritis started out costing about $10,000 a year. Ten years later, they list for more than $40,000.
As biosimilar products reach the market and rival more established RA treatments, the players are exploring legal challenges involving antitrust and anti-competitive behavior.
Each hospital will have its payments reduced by 1 percent for the year.
Controversial research methods by university researcher unlikely to prompt federal response or institutional change, experts say.
Patients are often aggressively screened for cancer, even if they won’t live long enough to benefit.
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.
These accounts are exempt from taxes and linked to high-deductible health plans. Republicans tried last summer in their unsuccessful efforts to replace the health law to make the accounts more enticing for consumers, but they didn’t make those changes in the current tax bill.
© 2026 KFF